Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 03:03 ET | Source: Hofseth Biocare ASA

Ex. Subsequent Offering Today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR...
October 27, 2025 03:02 ET | Source: Hofseth Biocare ASA

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR...
October 27, 2025 03:01 ET | Source: Hofseth Biocare ASA

Hofseth BioCare ASA: Disclosures of Large Shareholdings

Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new...
October 27, 2025 03:00 ET | Source: Hofseth Biocare ASA

Hofseth BioCare ASA: Private placement successfully placed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR...
October 24, 2025 11:56 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR...
October 24, 2025 11:48 ET | Source: Hofseth Biocare ASA

Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR...
September 17, 2025 02:55 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER

AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This...
September 09, 2025 02:58 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways

HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs...
September 04, 2025 05:36 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn

HBC is delighted to announce the appointment of Paul Bruhn as Head of New Business Development. Mr Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis...
August 22, 2025 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT

HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million,...